Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
Ionis Pharmaceuticals Inc (NASDAQ:IONS) released results from a Phase 2 study of ION224, an investigational DGAT2 antisense inhibitor for metabolic dysfunction-associated steatohepatitis (MASH), previously referred to as nonalcoholic steatohepatitis (NASH).
The study met its primary endpoint at both doses (120 mg and 90 mg), achieving liver histologic improvement, and also met the important secondary endpoint of MASH resolution.
Key highlights from the 160-patient study at 51 weeks included:
ION224 was safe and well-tolerated in MASH participants. Those in the ION224 study arms did not experience any worsening of hepatic or renal function or gastrointestinal side effects, and there was a lower rate of early termination compared to placebo.
Additionally, there were no on-study deaths or treatment-related serious adverse events.
Price Action: IONS shares are up 1.34% at $43.75 on the last check Wednesday.
Photo by Christina Victoria Craft on Unsplash
Posted In: IONS